Drotrecogin alfa (activated) for the treatment of severe sepsis in adults

Citation

(2006), "Drotrecogin alfa (activated) for the treatment of severe sepsis in adults", Clinical Governance: An International Journal, Vol. 11 No. 3. https://doi.org/10.1108/cgij.2006.24811cae.011

Drotrecogin alfa (activated) for the treatment of severe sepsis in adults

C. Green, J. Dinnes, A. Takeda, J. Shepherd, D. Hartwell, C. Cave, E. Payne and B.H. CuthbertsonHealth Technology Assessment2005Vol. 9 No. 11pp. 1-140

This review concluded that drotrecogin alfa (activated) is likely to be clinically effective and cost-effective for the treatment of patients with severe sepsis within the UK. The same conclusion applies to the subgroup of patients with severe sepsis and multiple organ failure. The authors stated that up to 16,570 patients per year could be eligible for treatment with drotrecogin alfa (activated) in England and Wales, with an estimated annual drug acquisition cost of over £80 million. The review was well conducted and the conclusions are likely to be reliable, but it should be borne in mind that the effectiveness conclusions are largely based on the results of a single large RCT.

Read the abstract in full at: http://nhscrd.york.ac.uk/online/dare/20058225.htm